As filed with the Securities and Exchange Commission on September 5, 2002
Registration No. 333-
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM S-3
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
--------------------------
BIOTIME, INC.
(Exact name of Registrant as specified in charter)
------------------------------------------------
California 94-3127919
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
Paul E. Segall, Chief Executive Officer
935 Pardee Street BioTime, Inc.
Berkeley, California 94710 935 Pardee Street
(510) 845-9535 Berkeley, California 94710
(Address, including zip code, (510) 845-9535
and telephone number, including area code, (Name, address, including zip code, and telephone number,
of Registrant's principal executive offices) including area code, of agent for service)
-------------------------
Copies of all communications, including all communications sent to the agent
for service, should be sent to:
RICHARD S. SOROKO, ESQ.
Lippenberger, Thompson, Welch, Soroko & Gilbert LLP
201 Tamal Vista Blvd.
Corte Madera, California 94925
Tel. (415) 927-5200
-------------------------
Approximate date of commencement of proposed sale to the public: As soon as
practicable after this Registration Statement becomes effective.
If the only securities being registered on this Form are being offered pursuant
to dividend or interest reinvestment plans, please check the following box. [ ]
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 of the Securities Act of 1933,
other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
==============================================================================================================================
Proposed
Amount Proposed Maximum Amount of
to be Maximum Offering Aggregate Registration
Title of Each Class of Securities to be Registered Registered Price Per Unit(1) Offering Price(1) Fee(2)
------------------------------------------------------------------------------------------------------------------------------
Common Shares, no par value 2,452,785 $1.45 $3,556,538.25 $327.20
------------------------------------------------------------------------------------------------------------------------------
Warrant to Purchase Common Shares 129,695 -- -- --
------------------------------------------------------------------------------------------------------------------------------
Common Shares, no par value(3) 129,695 $1.34 $173,791.30 $15.99
------------------------------------------------------------------------------------------------------------------------------
Warrant to Purchase Common Shares 30,000 -- -- --
------------------------------------------------------------------------------------------------------------------------------
Common Shares, no par value(3) 30,000 $4.00 $120,000 $11.04
------------------------------------------------------------------------------------------------------------------------------
Total Registration Fee .............................................................................................$354.23
==============================================================================================================================
(1) Estimated solely for the purpose of calculating the registration fee for
this Registration Statement.
(2) Determined pursuant to Rule 457(c) and (g), including the exercise prices of
the various Warrants.
(3) Issuable upon the exercise of the Warrants.
The Registrant hereby amends this Registration Statement on such date or dates
as may be necessary to delay its Effective Date until the Registrant shall file
a further amendment which specifically states that this Registration Statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933, or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
This Registration Statement relates to the registration statements under
Commission file numbers 333-44092 and 333-75300.
================================================================================
SUBJECT TO COMPLETION -- DATED SEPTEMBER 5, 2002
PROSPECTUS
BIOTIME, INC.
4,152,323 COMMON SHARES
725,078 WARRANTS TO PURCHASE COMMON SHARES
All of the shares and warrants offered by this prospectus are being
offered for sale by shareholders or warrant holders of BioTime, Inc. who may
sell their shares and warrants from time to time at prevailing market prices or
in privately negotiated transactions. Warrant holders may acquire shares by
exercising their warrants and may then sell those shares. The selling
shareholders and warrant holders will bear all broker-dealer fees, commissions,
and discounts payable in connection with the sale of their shares and warrants.
ALL OF THE NET PROCEEDS FROM THE SALE OF SHARES AND WARRANTS WILL BE
RECEIVED BY THE SELLING SHAREHOLDERS AND WARRANT HOLDERS, AND NONE OF THE NET
PROCEEDS WILL BE PAID TO BIOTIME, INC. ("BIOTIME"). HOWEVER, BIOTIME WILL
RECEIVE THE EXERCISE PRICE OF THE WARRANTS WHEN THE WARRANTS ARE EXERCISED.
THE COMMON SHARES ARE LISTED FOR TRADING ON THE AMERICAN STOCK EXCHANGE
(THE "AMEX") UNDER THE SYMBOL BTX. THE CLOSING PRICE OF THE COMMON SHARES ON THE
AMEX ON SEPTEMBER 4, 2002 WAS $1.42. THERE IS PRESENTLY NO PUBLIC MARKET FOR THE
WARRANTS, AND THERE IS NO EXPECTATION THAT A MARKET WILL DEVELOP.
----------------
THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK AND SHOULD BE PURCHASED ONLY BY
PERSONS WHO CAN AFFORD THE LOSS OF THEIR ENTIRE INVESTMENT. SEE "RISK FACTORS"
ON PAGE 5.
----------------
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
THE DATE OF THIS PROSPECTUS IS SEPTEMBER 5, 2002
PROSPECTUS SUMMARY
The following summary explains only some of the information in this
prospectus. More detailed information and financial statements appear elsewhere
in this prospectus or in the documents incorporated by reference into this
prospectus. Statements contained in this prospectus that are not historical
facts may constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Words such as "expects," "may," "will," "anticipates,""intends,"
"plans," "believes," "seeks," "estimates," and similar expressions identify
forward-looking statements. See "Risk Factors."
THE COMPANY
BioTime, Inc. is a development stage company engaged in the research and
development of synthetic solutions that can be used as blood plasma volume
expanders, blood replacement solutions during hypothermic (low temperature)
surgery, and organ preservation solutions. Plasma volume expanders are used to
treat blood loss in surgical or trauma patients until blood loss becomes so
severe that a transfusion of packed red blood cells or other blood products is
required. We are also developing a specially formulated hypothermic blood
substitute solution that would have a similar function and would be used for the
replacement of very large volumes of a patient's blood during cardiac surgery,
neurosurgery and other surgeries that involve lowering the patient's body
temperature to hypothermic levels.
Our first product, Hextend(R), is a physiologically balanced blood plasma
volume expander, for the treatment of hypovolemia. Hypovolemia is a condition
often associated with blood loss during surgery or from injury. Hextend
maintains circulatory system fluid volume and oncotic pressure and keeps vital
organs perfused during surgery. Hextend, approved for use in major surgery, is
the only blood plasma volume expander that contains hetastarch, buffer, multiple
electrolytes and glucose. Hextend is designed to compete with and to replace
products such as albumin and other colloid solutions, as well as crystalloid
solutions, that have been used to maintain fluid volume and blood pressure
during surgery.
Hextend is being sold in the United States by Abbott Laboratories under an
exclusive license from us. Abbott also has the right to sell Hextend in Canada,
where marketing approval has recently been received. Abbott also has a right to
obtain licenses to manufacture and sell other BioTime products in the United
States and Canada. We have retained all rights to manufacture, sell or license
Hextend and other products in all other countries.
Because Hextend is a surgical product, sales will be determined by
anesthesiologists, surgeons practicing a variety of specialties, and hospital
pharmacists. Abbott's marketing strategy is designed to reach this target
customer base through sales calls and an advertising campaign focused on the
physiological basis of using a plasma-like substance to replace lost blood
volume and the ability of Hextend to support vital physiological processes.
3
As part of the marketing program, Abbott and BioTime have financed a
number of studies showing the advantages of receiving Hextend and other BioTime
products during surgery. The results of these studies will be presented at
medical conferences and articles will be written for publication in medical
journals. BioTime is also aware of independent studies using Hextend that are
being conducted by physicians and hospitals, who may publish their findings in
medical journals. The outcome of medical studies and timing of the publication
of the results could have an effect on Hextend sales.
We are also developing two other blood volume replacement products,
PentaLyte,(R) and HetaCool,(TM) that, like Hextend,(R) have been formulated to
maintain the patient's tissue and organ function by sustaining the patient's
fluid volume and physiological balance. Various colloid and crystalloid products
are being marketed by other companies for use in maintaining patient fluid
volume in surgery and trauma care, but the use of those solutions can contribute
to patient morbidity, including conditions such as hypovolemia, edema, impaired
blood clotting, acidosis, and other biochemical imbalances. Hextend, PentaLyte,
and HetaCool contain constituents that may prevent or reduce the physiological
imbalances that can cause those problems. Our products do not contain albumin.
Albumin produced from human plasma is also currently used as a plasma expander,
but it is expensive and subject to supply shortages, and an FDA warning has
cautioned physicians about the risk of administering albumin to seriously ill
patients.
BioTime was incorporated under the laws of the State of California on
November 30, 1990. BioTime's principal office is located at 935 Pardee Street,
Berkeley, California 94710. Its telephone number is (510) 845-9535.
Hextend(R) and PentaLyte(R) are registered trademarks, and HetaCool(TM) is
a trademark, of BioTime, Inc.
EXERCISE OF WARRANTS AND SALE OF THE SHARES
The shares offered by this prospectus include both shares presently owned
by certain selling shareholders and shares that may be issued to the holders of
certain warrants upon the exercise of their warrants. The registration of the
shares will permit the selling shareholders and warrant holders to sell shares
(including shares they may acquire upon the exercise of their warrants) and the
warrants from time to time. Shares may be sold on the AMEX at prevailing market
prices or at prices related to the prevailing market price or in privately
negotiated transactions. The warrants may be sold in over the counter or in
privately negotiated transactions, subject to restrictions on transfer that
apply to one of the warrants. There is presently no public market for the
warrants. BioTime has agreed to apply to list certain warrants on the AMEX at
the request of any holder of those warrants if the AMEX listing requirements are
met. As of the date of this prospectus, the AMEX listing requirements applicable
to the warrants have not been met. The AMEX rules presently provide that the
AMEX will not list warrants unless there are at least 200,000 warrants publicly
held by not less than 100 public warrant holders. The selling shareholders and
warrant holders will bear all broker-dealer commissions payable in connection
with the sale of their shares and the warrants. See "Selling Shareholders" and
"Plan of Distribution" for more information about the selling shareholders' plan
to sell shares and warrants.
4
RISK FACTORS
AN INVESTMENT IN THE SHARES AND WARRANTS INVOLVES A HIGH DEGREE OF RISK.
YOU SHOULD PURCHASE THE SHARES AND WARRANTS ONLY IF YOU CAN AFFORD TO LOSE YOUR
ENTIRE INVESTMENT. BEFORE DECIDING TO PURCHASE ANY OF THE SHARES OR WARRANTS
OFFERED BY THIS PROSPECTUS, YOU SHOULD CONSIDER THE FOLLOWING FACTORS WHICH
COULD MATERIALLY ADVERSELY AFFECT THE PROPOSED OPERATIONS AND PROSPECTS OF
BIOTIME AND THE VALUE OF AN INVESTMENT IN BIOTIME.
WE MAY NOT SUCCEED IN MARKETING OUR PRODUCTS DUE TO THE AVAILABILITY OF
COMPETING PRODUCTS
Our ability to generate operating revenue depends upon our success in
developing and marketing our products. There can be no assurance that any of our
products will be successfully marketed or that we will receive sufficient
revenues from product sales to meet our operating expenses or to earn a profit.
In this regard, sales of Hextend to date have not been sufficient to generate an
amount of royalties or licensing fees sufficient to cover our operating
expenses.
- Hextend and our other plasma expander products will compete with
other products, including albumin and other colloid solutions, and
crystalloid solutions. Some of these products, in particular
crystalloid solutions and generic hetastarch in saline solutions,
are commonly used in surgery and trauma care and sell at low prices.
- In order to compete with other products, particularly those that
sell at lower prices, BioTime products will have to provide
medically significant advantages.
- Physicians and hospitals may be reluctant to try a new product due
to the high degree of risk associated with the application of new
technologies and products in the field of human medicine.
- Competing products are being manufactured and marketed by
established pharmaceutical companies. For example, B. Braun/McGaw
presently markets Hespan, an artificial plasma volume expander, and
Abbott and Baxter International, Inc. manufacture and sell a generic
equivalent of Hespan.
- There also is a risk that our competitors may succeed in developing
safer or more effective products that could render our products and
technologies obsolete or noncompetitive.
WE WILL SPEND A SUBSTANTIAL AMOUNT OF OUR CAPITAL ON RESEARCH AND DEVELOPMENT
BUT WE MIGHT NOT SUCCEED IN DEVELOPING PRODUCTS AND TECHNOLOGIES THAT ARE USEFUL
IN MEDICINE.
- We are attempting to develop new medical products and technologies.
- Many of our experimental products and technologies have not been
applied in human medicine and have only been used in laboratory
studies on animals, and there can be no
5
assurance that those products will prove to be safe and efficacious
in the human medical applications for which they were developed.
- The experimentation we are doing is costly, time consuming and
uncertain as to its results.
- If we are successful in developing a new technology or product,
refinement of the new technology or product and definition of the
practical applications and limitations of the technology or product
may take years and require the expenditure of large sums of money.
IF WE DO NOT RECEIVE FDA AND OTHER REGULATORY APPROVALS WE WILL NOT BE PERMITTED
TO SELL OUR PRODUCTS
The products that we develop cannot be sold until the FDA and
corresponding foreign regulatory authorities approve the products for medical
use. This means that:
- We will have to conduct expensive and time consuming clinical trials
of new products;
- We will incur the expense and delay inherent in seeking FDA approval
of new products;
- A product that is approved may be subject to restrictions on use;
- The FDA can recall or withdraw approval of a product if problems
arise; and
- We will face similar regulatory issues in foreign countries.
WE MIGHT NOT BE ABLE TO RAISE ADDITIONAL CAPITAL NEEDED TO PAY OUR OPERATING
EXPENSES
We plan to continue to incur substantial research, product development,
and regulatory expenses, and we will need to raise additional capital to pay
operating expenses until we are able to generate sufficient revenues from
product sales, royalties, and license fees. We have not received an amount of
royalties and licensing fees from the sale of Hextend sufficient to cover our
operating expenses. We will have to curtail the pace of our product development
efforts unless our cash resources increase through a growth in revenues or
additional equity investment or borrowing. Although we will continue to seek
licensing fees from pharmaceutical companies for licenses to manufacture and
market our products abroad, it is likely that additional sales of equity or debt
securities will be required to meet our short-term capital needs. Sales of
additional equity securities could result in the dilution of the interests of
present shareholders. There can be no assurance that we will be able to raise
additional funds on favorable terms or at all, or that any funds raised will be
sufficient to permit us to develop and market our products. Unless we are able
to generate sufficient revenue or raise additional funds when needed, it is
likely that we will be unable to continue our planned activities, even if we are
making progress with our research and development projects.
6
IF WE ARE UNABLE TO ENTER INTO ADDITIONAL LICENSING OR MANUFACTURING
ARRANGEMENTS, WE MAY HAVE TO INCUR SIGNIFICANT EXPENSE TO ACQUIRE MANUFACTURING
FACILITIES AND A MARKETING ORGANIZATION
We presently do not have adequate facilities or resources to manufacture
our products and the hydroxyethyl starches used in our products. We plan to
enter into arrangements with pharmaceutical companies for the production and
marketing of our products. We have granted Abbott an exclusive license to
manufacture and market Hextend in the United States and Canada. Although a
number of pharmaceutical companies have expressed their interest in obtaining
licenses to manufacture and market our products in other countries, there can be
no assurance that we will be successful making other licensing arrangements. If
licensing or manufacturing arrangements cannot be made on acceptable terms, we
will have to construct or acquire our own manufacturing facilities and establish
our own marketing organization, which would entail significant expenditures of
time and money.
OUR PATENTS MAY NOT PROTECT OUR PRODUCTS FROM COMPETITION
We have patents in Australia, Israel, Russia, South Africa, South Korea,
and the United States and have filed patent applications in other foreign
countries, for certain products, including Hextend, HetaCool, and PentaLyte. No
assurance can be given that any additional patents will be issued to us, or
that, if issued, those patents will provide us with meaningful patent
protection, or that others will not successfully challenge the validity or
enforceability of any patent issued to us. The costs required to uphold the
validity and prevent infringement of any patent issued to us could be
substantial, and we might not have the resources available to defend our patent
rights.
THE PRICE AND SALE OF OUR PRODUCTS MAY BE LIMITED BY HEALTH INSURANCE COVERAGE
AND GOVERNMENT REGULATION
Success in selling our products may depend in part on the extent to which
health insurance companies, HMOs, and government health administration
authorities such as Medicare and Medicaid will pay for the cost of the products
and related treatment. Presently, most health insurance plans and HMOs will pay
for Hextend when it is used in a surgical procedure that is covered by the plan.
However, there can be no assurance that adequate health insurance, HMO, and
government coverage will be available to permit our other products to be sold at
prices high enough for us to generate a profit. In some foreign countries,
pricing or profitability of health care products is subject to government
control which may result in low prices for our products. In the United States,
there have been a number of federal and state proposals to implement similar
government controls, and new proposals are likely to be made in the future.
OUR BUSINESS COULD BE ADVERSELY AFFECTED IF WE LOSE THE SERVICES OF THE KEY
PERSONNEL UPON WHOM WE DEPEND
We depend to a considerable degree on the continued services of executive
officers, especially our Chief Executive Officer. The loss of the services of
any of the executive officers could have a material adverse effect on us. In
addition, our success will depend, among other factors, upon
7
successful recruitment and retention of additional highly skilled and
experienced management and technical personnel.
BECAUSE WE DO NOT PAY DIVIDENDS, OUR STOCK MAY NOT BE A SUITABLE INVESTMENT FOR
ANYONE WHO NEEDS TO EARN DIVIDEND INCOME
We do not pay cash dividends on our common shares. For the foreseeable
future we anticipate that any earnings generated in our business will be used to
finance the growth of BioTime and will not be paid out as dividends to our
shareholders. We have also agreed not to declare or pay any cash dividends on
our capital stock or to redeem or repurchase any shares of our capital stock,
until we have paid off our debenture indebtedness in full. This means that our
stock may not be a suitable investment for anyone who needs to earn income from
their investments.
BECAUSE WE ARE A DRUG DEVELOPMENT COMPANY, THE PRICE OF OUR STOCK MAY RISE AND
FALL RAPIDLY
The market price of BioTime shares, like that of the common stock of many
biotechnology companies, has been highly volatile. The price of BioTime shares
may rise rapidly in response to certain events, such as the commencement of
clinical trials of an experimental new drug, even though the outcome of those
trials and the likelihood of ultimate FDA approval remains uncertain. Similarly,
prices of BioTime shares may fall rapidly in response to certain events such as
unfavorable results of clinical trials or a delay or failure to obtain FDA
approval. The failure of our earnings to meet analysts' expectations could
result in a significant rapid decline in the market price of our common shares.
In addition, the stock market has experienced and continues to experience
extreme price and volume fluctuations which have affected the market price of
the equity securities of many biotechnology companies and which have often been
unrelated to the operating performance of these companies. Broad market
fluctuations, as well as general economic and political conditions, may
adversely affect the market price of the common shares.
8
THE COMPANY
We are developing synthetic solutions that can be used as blood plasma
volume expanders, blood replacement solutions during "hypothermic" or low
temperature surgery, and organ preservation solutions. Plasma volume expanders
are used to treat blood loss in surgical or trauma patients until blood loss
becomes so severe that a transfusion of packed red blood cells or other blood
products is required. We are also developing a specially formulated hypothermic
blood replacement solution that would be used for the replacement of a patient's
circulating blood volume during cardiac surgery, neurosurgery and other
surgeries that involve lowering the patient's body temperature to hypothermic
levels.
Our first product, Hextend, is a physiologically balanced blood plasma
volume expander, for the treatment of hypovolemia. Hypovolemia is a condition
often associated with blood loss during surgery or from injury. Hextend
maintains circulatory system fluid volume and oncotic pressure and keeps vital
organs perfused during surgery. Hextend, approved for large-volume use in major
surgery, is the only blood plasma volume expander that contains hetastarch,
buffer, multiple electrolytes and glucose. Hextend is designed to compete with
and to replace older products such as albumin and other colloid solutions, as
well as crystalloid solutions, that have been used to maintain fluid volume and
blood pressure during surgery. Hextend is also completely sterile to avoid risk
of infection. Most health insurance reimbursements and HMO coverage now include
the cost of Hextend used in surgical procedures.
Hextend is being sold in the United States by Abbott under an exclusive
license from us. Abbott also has the right to sell Hextend in Canada. We have
retained all rights to manufacture, sell or license Hextend and other products
in all other countries. Abbott also has a right to obtain licenses to
manufacture and sell other BioTime products.
Because Hextend is a surgical product, sales will be determined by
anesthesiologists, surgeons practicing a variety of specialties, and hospital
pharmacists. Abbott's marketing strategy is designed to reach this target
customer base through sales calls and an advertising campaign focused on the
physiological basis of using a plasma-like substance to replace lost blood
volume and the ability of Hextend to support vital physiological processes.
As part of the marketing program, a number of studies have been conducted
showing the advantages of receiving Hextend and other BioTime products during
surgery. As these studies are completed, the results will be presented at
medical conferences and articles will be written for publication in medical
journals. The Company is also aware of independent studies using Hextend that
are being conducted by physicians and hospitals, who may publish their findings
in medical journals. The outcome of medical studies and timing of the
publication of the results could have an effect on Hextend sales.
We are also developing two other blood volume replacement products,
PentaLyte and HetaCool that, like Hextend, have been formulated to maintain the
patient's tissue and organ function by sustaining the patient's fluid volume and
physiological balance. Various colloid and crystalloid products are being
marketed by other companies for use in maintaining patient
9
fluid volume in surgery and trauma care, but the use of those solutions can
contribute to patient morbidity, including conditions such as hypovolemia,
edema, impaired blood clotting, acidosis, and other biochemical imbalances.
Hextend, PentaLyte, and HetaCool contain constituents that may prevent or reduce
the physiological imbalances that can cause those problems. Our products do not
contain albumin. Albumin produced from human plasma is also currently used as a
plasma expander, but it is expensive and subject to supply shortages, and a
recent FDA warning has cautioned physicians about the risk of administering
albumin to seriously ill patients.
Based upon the results of our clinical studies and laboratory research, we
have determined that in many emergency care and surgical applications it is not
necessary for a plasma volume expander to include special oxygen carrying
molecules to replace red blood cells. Therefore, we are developing formulations
that do not use costly and potentially toxic oxygen carrying molecules such as
synthetic hemoglobin and perfluorocarbons.
We have completed a Phase I clinical trial of PentaLyte and are planning
the next phase of our clinical trials in which PentaLyte will be used to treat
hypovolemia in surgery. PentaLyte contains a lower molecular weight hydroxyethyl
starch than Hextend, and is more quickly metabolized. PentaLyte is designed for
use when short lasting volume expansion is desirable.
We are also continuing to develop solutions for low temperature surgery
and trauma care. A number of physicians have reported using Hextend to treat
hypovolemia under mild hypothermic conditions during cardiac surgery. Additional
cardiac surgeries have been performed at deeper hypothermic temperatures. Once a
sufficient amount of data from successful low temperature surgery has been
compiled, we plan to seek permission to conduct trials using Hextend as a
complete replacement for blood under near-freezing conditions. We currently plan
to market Hextend for complete blood volume replacement at very low temperatures
under the registered trade mark "HetaCool(R)" after FDA approval is obtained.
In order to commence clinical trials for regulatory approval of new
products, such as PentaLyte and HetaCool, or new therapeutic uses of Hextend, it
will be necessary for us to prepare and file with the FDA an Investigational New
Drug Application ("IND") or an amendment to expand the present IND for
additional Hextend studies. Filings with foreign regulatory agencies will be
required to commence clinical trials overseas.
We intend to enter global markets through licensing agreements with
overseas pharmaceutical companies. By licensing our products abroad, we will
avoid the capital costs and delays inherent in acquiring or establishing our own
pharmaceutical manufacturing facilities and establishing an international
marketing organization. A number of pharmaceutical companies around the world
have expressed their interest in obtaining licenses to manufacture and market
our products. Our management is continuing to meet with representatives of
interested companies.
We are also pursuing a global clinical trial strategy, the goal of which
is to permit us to obtain regulatory approval for our products as quickly and
economically as practicable. For
10
example, the United States Phase III clinical trials of Hextend involved 120
patients and were completed in less than 12 months. Although regulatory
requirements vary from country to country, we may be able to file applications
for foreign regulatory approval of its products based upon the results of the
United States clinical trials.
The cost of preparing regulatory filings and conducting clinical trials is
not presently determinable, but could be substantial. It may be necessary for us
to obtain additional funds in order to complete any clinical trials that it may
conduct for its new products or for new uses of Hextend.
In addition to developing clinical trial programs, we plan to continue to
provide funding for our laboratory testing programs at selected universities,
medical schools and hospitals for the purpose of developing additional uses of
Hextend, PentaLyte, HetaCool, and other new products, but the amount of research
that will be conducted at those institutions will depend upon our financial
status. Because our research and development expenses, clinical trial expenses,
and production and marketing expenses will be charged against earnings for
financial reporting purposes, management expects that losses from operations
will continue to be incurred for the foreseeable future.
11
USE OF PROCEEDS
The shares are being offered for sale by the selling shareholders. BioTime
will not receive any of the net proceeds from the sale of the shares or the
warrants. We will receive the exercise price of the warrants when they are
exercised. If all of the warrants are exercised in full, we would receive
$4,059,281. However, there is no assurance that the warrants will be exercised.
We will use the proceeds we receive from the exercise of the warrants for
general working capital purposes, including research and development expenses
and general and administrative expenses.
SELLING SHAREHOLDERS AND WARRANT HOLDERS
The following table shows the number of shares and warrants owned by the
selling shareholders and warrant holders prior to this offering, the maximum
number of shares and warrants that may be sold by them through this prospectus,
and the amount and percentage of the outstanding shares that will be owned by
them after the completion of this offering assuming all of the shares covered by
this prospectus are sold.
Shares and
Shares and Shares and Warrants Percent of Shares
Warrants Warrants Owned After Owned After
Name Owned Offered Offering Offering
---- ---------- ---------- ----------- -----------------
Isaac Abishour 1,750 1,750 0 0%
Art Agajanian 60,000 60,000 0 0%
Joseph Berland 99,729 99,729 0 0%
Michael T. Berns 3,000 3,000 0 0%
Harold S. Berzow 4,000 4,000 0 0%
Dorothy Breslin 13,500 13,500 0 0%
Camco Tactical Return Partners, L.P. 615,688(1) 346,923(1) 268,765 2.0%
Donald E. Cohen 9,000 9,000 0 0%
Thomas A. and Elizabeth Colacino 2,200 2,200 0 0%
Cyndel & Co., Inc. 65,200(2) 50,000 15,200(2) less than 1%
Milton Dresner 86,873(3) 15,384(3) 71,489 less than 1%
Field and Field 17,500 17,500 0 0%
Richard and Linda Gearns 10,000 10,000 0 0%
Goren Brothers, L.P. 38,461(4) 38,461(4) 0 0%
Grand Slam Capital Partners, L.P. 650,000 650,000 0 0%
Paul Graf 72,004 50,000 22,004 less than 1%
Peter Graf 58,108 50,000 8,108 less than 1%
Terence Hall 75,000 75,000 0 0%
Ingersoll Family Trust 11,000 11,000 0 0%
David Jacobson 35,000 35,000 0 0%
Erika Jorgenson 15,000 15,000 0 0%
George Karfunkel 76,923(4) 76,923(4) 0 0%
Alfred D. Kingsley 2,975,583(5) 1,974,514(6) 1,001,069 7.3%
Gary K. Duberstein 0 0%
Greenbelt Corp. 0 0%
Greenway Partners, L.P. 0 0%
Greenhouse Partners, L.P. 0 0%
James Kousouros 30,000 30,000 0 0%
12
Shares and
Shares and Shares and Warrants Percent of Shares
Warrants Warrants Owned After Owned After
Name Owned Offered Offering Offering
---- ---------- ---------- ----------- -----------------
Edward F. Koziol 22,321 22,321 0 0%
Ladenburg Thalmann & Co., Inc. 129,695(4) 129,695(4) 0 0%
C. J. Mahoney and Carol Celeste 7,000 7,000 0 0%
George L. Malin 25,000 25,000 0 0%
Richard Mayeri 18,500 18,000 500 less than 1%
Jeffrey B. Nickel 56,666(7) 10,000 0 0%
John S. and Stella C. Patterson 20,000 20,000 0 0%
Steven Richman 457,000 100,000 357,000 2.6%
Martin Schackner 10,000 10,000 0 0%
Daniel R. Schmidt 12,000 12,000 0 0%
Michael P. Silva 800 800 0 0%
Kenneth Sperber 40,000 40,000 0 0%
Dennis Spina 30,000 30,000 0 0%
Howard Stein 76,923(4) 76,923(4) 0 0%
Harold V. Sullivan, Jr. 1,700 1,700 0 0%
Amy Taus 5,000 5,000 0 0%
Ray Y. Yamada 5,000 5,000 0 0%
(1) Includes 76,923 common shares that may be acquired upon the exercise of
certain warrants.
(2) Includes 15,200 shares held in Cyndel & Co. Inc. Pension and Profit Sharing
Trust. Excludes 27,700 shares beneficially owned by family members of a
shareholder of Cyndel & Co., Inc. and 15,200 shares held by a corporation
controlled by the shareholders of Cyndel & Co., Inc.
(3) Includes 46,666 common shares issuable upon the exercise of stock options
that are currently exercisable or become exercisable within 60 days, and 15,384
common shares issuable upon the exercise of certain warrants. Mr. Dresner is a
director of BioTime.
(4) All of the shares may be acquired and sold by the selling shareholder upon
the exercise of certain warrants.
(5) Includes 674,460 common shares owned by Greenbelt Corp., 90,750 common
shares owned by Greenway Partners, L.P., 1,888,709 common shares owned solely by
Alfred D. Kingsley, 310,769 common shares issuable upon the exercise of certain
warrants owned solely by Mr. Kingsley, and 10,895 common shares owned solely by
Gary K. Duberstein. Alfred D. Kingsley and Gary K. Duberstein control Greenbelt
Corp. and may be deemed to beneficially own the shares that Greenbelt Corp.
owns. Greenhouse Partners, L.P. is the general partner of Greenway Partners,
L.P., and Mr. Kingsley and Mr. Duberstein control Greenhouse Partners, L.P.
Greenhouse Partners, L.P., Mr. Kingsley, and Mr. Duberstein may be deemed to
beneficially own the shares that Greenway Partners, L.P. owns. Mr. Duberstein
disclaims beneficial ownership of the shares and warrants owned solely by Mr.
Kingsley, and Mr. Kingsley disclaims beneficial ownership of the shares owned
solely by Mr. Duberstein.
(6) Includes 674,460 shares owned by Greenbelt Corp., 989,285 shares owned
solely by Alfred Kingsley, and 310,769 shares that may be acquired by Alfred
Kingsley upon the exercise of certain warrants.
(7) Includes 46,666 common shares issuable upon the exercise of stock options
that are currently exercisable or become exercisable within 60 days. Dr. Nickel
is a director of BioTime.
In connection with the issue of the warrants, we agreed to register the
warrants and underlying common shares for sale under the Securities Act of 1933,
as amended. We will bear the expenses of registration, other than any
underwriting discounts or commissions payable to broker-dealers that may be
incurred by the selling shareholders in connection with a sale of the
13
warrants or shares. We are not obligated to file more than two such registration
statements, other than registration statements on Form S-3. The selling
shareholders also are entitled to include warrants and shares in any
registration statement that we may file to register other securities for sale
under the Act.
During April 1998, we entered into a financial advisory services agreement
with Greenbelt Corp. The agreement provided for an initial payment of $90,000
followed by an advisory fee of $15,000 per month paid quarterly. We agreed to
reimburse Greenbelt Corp. for all reasonable out-of-pocket expenses incurred in
connection with its engagement as financial advisor, and to indemnify Greenbelt
Corp. and its officers, affiliates, employees, agents, assignees, and
controlling person from any liabilities arising out of or in connection with
actions taken on our behalf under the agreement. The agreement was renewed twice
for the twelve months ending March 31, 2001 and March 31, 2002, but instead of
cash compensation Greenbelt Corp. has received 70,000 common shares. We agreed
to register those shares for sale under the Act, and those shares are covered by
this prospectus. We have also agreed to permit Alfred D. Kingsley to include in
this registration an additional 900,000 common shares that he acquired from
certain BioTime officers and directors who sold their shares to reduce margin
account indebtedness.
DESCRIPTION OF THE WARRANTS
The following is a brief summary of the terms of the warrants. This
summary is not intended as a complete description of the warrants and is
qualified by the terms of the warrants. Each warrant holder and each prospective
purchaser of a warrant should read the entire applicable warrant.
WARRANTS ISSUED TO ALFRED D. KINGSLEY
Alfred D. Kingsley holds two warrants, one of which entitles him to
purchase 50,000 common shares and one of which entitles him to purchase 30,000
common shares. The terms of these two warrants are the same, except for the
number of shares, exercise prices and expiration dates. These warrants was
issued in connection with lines of credit extended by Mr. Kingsley and are
referred to below as the "Line of Credit Warrants."
Exercise Price. The exercise prices of the Line of Credit Warrants are
$8.31 per share and $4.00 per share, respectively.
Adjustments. The exercise price and the number and kind of shares which
may be purchased upon the exercise of the Line of Credit Warrants are subject to
adjustment to prevent dilution in the event of a stock split, combination, stock
dividend, reclassification of shares, sale of assets, merger, or similar
transaction.
How to Exercise the Line of Credit Warrants. The Line of Credit Warrants
may be exercised in whole or in part by presentation of the warrant certificate
with the purchase form duly executed and simultaneous payment of the exercise
price. The Line of Credit Warrant holder's signature must be guaranteed by a
bank or trust company or a broker or dealer which is
14
a member of the National Association of Securities Dealers, Inc. Payment must be
made at the principal office of BioTime (or if a warrant agent is appointed, at
the principal office of the warrant agent). Payment of the exercise price may be
made in cash or by certified or bank cashier's check.
If a Line of Credit Warrant is exercised for less than all of the shares
purchasable on such exercise at any time prior to the date of expiration of the
Line of Credit Warrant, a new certificate evidencing the unexercised portion of
the Line of Credit Warrant will be issued.
Expiration Dates. One Line of Credit Warrant will expire at 5:00 p.m., New
York time, on March 26, 2006, and one Line of Credit Warrant will expire at 5:00
p.m., New York time, on March 27, 2007. A Line of Credit Warrant may not be
exercised after its applicable expiration date.
WARRANTS ISSUED TO DEBENTURE HOLDERS
During August 2001, BioTime issued $3,350,000 in principal amount of
debentures. Purchasers of the debentures received warrants entitling them to
purchase an aggregate of 515,385 BioTime common shares. These warrants are
referred to below as the "Debenture Warrants."
Exercise Price. The exercise price of the Debenture Warrants is $6.50 per
share.
Adjustments. The exercise price and the number and kind of shares which
may be purchased upon the exercise of the Debenture Warrants are subject to
adjustment to prevent dilution in the event of a stock split, combination, stock
dividend, reclassification of shares, sale of assets, merger, or similar
transaction.
How to Exercise the Debenture Warrants. The Debenture Warrants may be
exercised in whole or in part by presentation of the warrant certificate with
the purchase form duly executed and simultaneous payment of the exercise price.
The warrant holder's signature must be guaranteed by a bank or trust company or
a broker or dealer which is a member of the National Association of Securities
Dealers, Inc. Payment must be made at the principal office of BioTime (or if a
warrant agent is appointed, at the principal office of the warrant agent).
Payment of the exercise price may be made in cash or by certified or bank
cashier's check. Holders of the debentures may pay the exercise price by
delivery of debentures in the amount of the exercise price.
If a Debenture Warrant is exercised for less than all of the shares
purchasable on such exercise at any time prior to the date of expiration of the
Debenture Warrant, a new certificate evidencing the unexercised portion of the
Debenture Warrant will be issued.
Expiration Date. The Debenture Warrants will expire at 5:00 p.m., New York
time, on August 1, 2004 and may not be exercised after that date.
15
Right to Redeem. The Debenture Warrants may be redeemed by BioTime, at its
election, at any time after June 30, 2002 if (a) a registration statement that
includes the Debenture Warrants and the underlying common shares is then
effective under the Securities Act of 1933, as amended, and (b) the closing
price of the common shares on a national securities exchange or the Nasdaq Stock
Market National Market System, or the average bid price as quoted in the Nasdaq
Stock Market if the common shares are not listed on a national securities
exchange, equals or exceeds 150% of the exercise price for any 15 consecutive
trading days. If BioTime desires to redeem the Debenture Warrants it must give
the Debenture Warrant holders notice of redemption by first class mail. Notice
will be sent to the Debenture Warrant holder's address appearing in the records
of BioTime or the warrant agent, if any. The notice shall be sent not less than
45 days prior to the date fixed by BioTime for redemption (the "Redemption
Date"). The redemption notice will state (i) the date of redemption, (ii) the
redemption price, (iii) the place or places at which the redemption price will
be paid upon presentation and surrender of the Debenture Warrants, and (iv) the
name and address of the warrant agent, if any, and the name and address of any
bank or trust company appointed by BioTime to receive and disburse the
redemption price.
The Redemption Date will abate, and the notice of redemption will be of no
effect, if the closing price or average bid price of the common shares does not
equal or exceed 120% of the exercise price on the Redemption Date and each of
the five trading days immediately preceding the Redemption Date, but BioTime
will have the right to redeem the Debenture Warrants at a future date if the
conditions for redemption described above are subsequently met and a new notice
setting a new Redemption Date is sent to Debenture Warrant holders.
From and after the Redemption Date, the Debenture Warrants will no longer
be exercisable and the holders of the Debenture Warrants will receive payment of
the redemption price of one cent ($0.01) per share upon presentation and
surrender of the Debenture Warrants.
LADENBURG THALMANN WARRANT
During August 2002, BioTime issued to Ladenburg Thalmann & Co., Inc., a
registered broker-dealer, a warrant to purchase 129,695 common shares as
compensation for serving as our agent in connection with a private placement of
common shares. This warrant is referred to as the Ladenburg Thalmann Warrant.
Exercise Price. The exercise prices of the Ladenburg Thalmann Warrant is
$1.34 per share.
Adjustment. The exercise price and the number and kind of shares which may
be purchased upon the exercise of the Ladenburg Thalmann Warrant are subject to
adjustment to prevent dilution in the event of a stock split, combination, stock
dividend, reclassification of shares, sale of assets, merger, or similar
transaction.
How to Exercise the Warrant. The Ladenburg Thalmann Warrant may be
exercised in whole or in part by presentation of the warrant with the purchase
form duly executed and simultaneous payment of the exercise price. Payment must
be made at the principal office of BioTime (or if a
16
warrant agent is appointed, at the principal office of the warrant agent).
Payment of the exercise price may be made in cash or by certified or bank
cashier's check.
If a warrant is exercised for less than all of the shares purchasable on
such exercise at any time prior to the date of expiration of the warrant, a new
certificate evidencing the unexercised portion of the warrant will be issued.
Expiration Date. The Ladenburg Thalmann Warrant will expire at 5:00 p.m.,
New York time, on August 11, 2007 and may not be exercised after that date.
Restrictions on Transfer. The Ladenburg Thalmann Warrant is not
transferable or assignable except (i) to Ladenburg Thalmann & Co. Inc., any
successor firm or corporation of Ladenburg Thalmann & Co. Inc. (ii) to any of
the officers or employees of Ladenburg Thalmann & Co. Inc. or of any such
successor firm or (iii) in the case of an individual, pursuant to such
individual's last will and testament or the laws of descent and distribution.
TRANSFER PROCEDURES APPLICABLE TO ALL OF THE WARRANTS
The warrants shall be transferable only on the warrant register maintained
by BioTime or a duly appointed warrant agent. Warrants to be transferred must be
delivered to BioTime (or the warrant agent if one has been appointed by
BioTime), duly endorsed by the holder or by his duly authorized attorney or
representative, or accompanied by proper evidence of succession, assignment or
authority to transfer, which endorsement shall be guaranteed by a bank or trust
company or a broker or dealer which is a member of the National Association of
Securities Dealers, Inc. In all cases of transfer by an attorney, the original
power of attorney, duly approved, or a copy thereof, duly certified, shall be
deposited and remain with BioTime (or the warrant agent, if appointed). In case
of transfer by executors, administrators, guardians or other legal
representatives, duly authenticated evidence of their authority shall be
produced, and may be required to be deposited and remain with BioTime (or the
warrant agent, if appointed) in its discretion. Upon any registration of
transfer, BioTime will execute and deliver (or if appointed, the warrant agent
shall countersign and deliver) a new warrant or warrants to the persons entitled
to receive them.
PLAN OF DISTRIBUTION
The selling shareholders have advised us that they plan to sell their
shares from time to time on the AMEX at prevailing market prices, or at prices
related to the prevailing market price, or in privately negotiated transactions.
The warrant holders have advised us that they may sell shares in conjunction
with the exercise of the warrants or they may hold their shares for investment
purposes and then sell the shares at a later date.
The Ladenburg Thalmann Warrant is subject to restrictions on transfer. See
"Description of the Warrants-Ladenburg Thalmann Warrant." Ladenburg Thalmann &
Co., Inc. may transfer its warrant, in whole or in part, to one or more of its
employees, as permitted by the Ladenburg Thalmann Warrant. The other warrant
holders may sell their warrants from time to time in
17
negotiated transactions at negotiated prices or, if a market for the warrants
develops, at prevailing market prices. No public market for the warrants
presently exists and there is no assurance that a public market will develop, or
if a public market develops, that it will be sustained.
The selling shareholders and warrant holders will bear all broker-dealer
commissions payable in connection with the sale of their shares and warrants.
Broker-dealers who acquire shares or warrants from the selling shareholders or
warrant holders as principals may resell the shares from time to time in
transactions on the AMEX, or may resell the shares or warrants in negotiated
transactions at prevailing market prices or at negotiated prices, and may
receive usual and customary commissions from the purchasers of the shares or
warrants.
The selling shareholders and warrant holders have advised us that during
the time that they may be engaged in a distribution of their shares and warrants
they will (a) not engage in any stabilization activity in connection with
BioTime securities, (b) cause to be furnished to each broker through whom their
shares or warrants may be offered the number of copies of this prospectus
required by the broker, and (c) not bid for or purchase any BioTime securities
or rights to acquire BioTime securities, or attempt to induce any person do so,
other than as permitted under the Securities Exchange Act of 1934, as amended.
The selling shareholders and warrant holders and any broker-dealers who
participate in the sale of their shares and warrants may be deemed to be
"underwriters" as defined in the Act. Any commissions paid or any discounts or
concessions allowed to any broker-dealers in connection with the sale of the
shares and warrants, and any profits received on the resale of any shares and
warrants purchased by broker-dealers as principals, may be deemed to be
underwriting discounts and commissions under the Act.
LEGAL MATTERS
The validity of the rights, common shares, and warrants will be passed
upon for BioTime by Lippenberger, Thompson, Welch, Soroko & Gilbert LLP, San
Francisco and Corte Madera, California.
EXPERTS
The financial statements incorporated in this prospectus by reference from
BioTime's Annual Report on Form 10-K/A-1 for the year ended December 31, 2001
have been audited by Deloitte & Touche LLP, independent auditors, as stated in
their report (which expresses an unqualified opinion and includes an explanatory
paragraph related to the development stage of BioTime's operations), which is
incorporated herein by reference, and have been so incorporated in reliance upon
the report of such firm given upon their authority as experts in accounting and
auditing.
18
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
BioTime's Form 10-K, as amended, for the fiscal year ended December 31,
2001 and all other reports filed by BioTime pursuant to Sections 13(a), 13(c),
14, or 15(d) of the Securities Exchange Act of 1934, as amended, since the end
of the fiscal year covered by such Form 10-K and prior to the termination of the
offering covered by this prospectus are hereby incorporated into this prospectus
by reference. A description of the common shares contained in a Registration
Statement on Form 8-A filed under the Securities Exchange Act of 1934, as
amended, is also incorporated into this prospectus by reference. BioTime will
provide without charge to each person, including any beneficial owner, to whom a
prospectus is delivered, upon written or oral request of such person, a copy of
any and all of the information that has been incorporated by reference but not
delivered with this prospectus. Such requests may be addressed to the Secretary
of BioTime at 935 Pardee Street, Berkeley, California 94710; Telephone: (510)
845-9535.
BioTime is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended, and in accordance therewith files quarterly,
annual, and current reports and proxy statements and other information with the
Securities and Exchange Commission. The public may read and copy any materials
BioTime files with Securities and Exchange Commission at the Commission's Public
Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. The public may
obtain information on the operation of the Public Reference Room by calling the
Commission at 1-800-SEC-0330.
The Commission maintains an Internet site that contains reports, proxy and
information statements, and other information regarding issuers that file
electronically with the Commission. The address of such site is
http://www.sec.gov.
ADDITIONAL INFORMATION
BioTime has filed with the Securities and Exchange Commission, 450 Fifth
Street, N.W., Washington, D.C. a registration statement on Form S-3 under the
Securities Act of 1933, as amended, for the registration of the securities
offered hereby. This prospectus, which is part of the registration statement,
does not contain all of the information contained in the registration statement.
For further information with respect to BioTime and the securities offered
hereby, reference is made to the registration statement, including the exhibits
thereto, which may be inspected, without charge, at the Office of the Securities
and Exchange Commission, or copies of which may be obtained from the Commission
in Washington, D.C. upon payment of the requisite fees. Statements contained in
this prospectus as to the content of any contract or other document referred to
are not necessarily complete. In each instance reference is made to the copy of
the contract or other document filed as an exhibit to the registration
statement, and each such statement is qualified in all respects by reference to
the exhibit.
19
================================================================================
No dealer, salesperson or other person has been authorized in connection with
this offering to give any information or to make any representations other than
those contained in this Prospectus. This Prospectus does not constitute an offer
or a solicitation in any jurisdiction to any person to whom it is unlawful to
make such an offer or solicitation. Neither the delivery of this Prospectus nor
any sale made hereunder shall, under any circumstances, create an implication
that there has been no change in the circumstances of BioTime or the facts
herein set forth since the date hereof.
TABLE OF CONTENTS
Prospectus Summary............................................... 3
Risk Factors..................................................... 5
The Company...................................................... 9
Use of Proceeds.................................................. 12
Selling Shareholders and Warrant Holders......................... 12
Description of the Warrants...................................... 14
Plan of Distribution............................................. 17
Legal Matters.................................................... 18
Experts.......................................................... 18
Incorporation of Certain Information by Reference................ 19
Additional Information........................................... 19
BIOTIME, INC.
4,152,323 Common Shares
725,078 Warrants
-------------
PROSPECTUS
-------------
September 5, 2002
================================================================================
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The estimated expenses of the Registrant in connection with the issuance
and distribution of the securities being registered hereby are as follows:
Registration Fee-Securities and Exchange Commission ..... $354.23
Accounting Fees.......................................... *
-------
Legal Fees............................................... *
-------
Miscellaneous Expenses................................... *
-------
Total.............................................. $ *
=======
----------
* To be filed by amendment.
Item 15. Indemnification of Directors and Officers.
Section 317 of the California Corporations Code permits indemnification of
directors, officers, employees and other agents of corporations under certain
conditions and subject to certain limitations. In addition, Section 204(a)(10)
of the California Corporations Code permits a corporation to provide, in its
articles of incorporation, that directors shall not have liability to the
corporation or its shareholders for monetary damages for breach of fiduciary
duty, subject to certain prescribed exceptions. Article Four of the Articles of
Incorporation of the Registrant contains provisions for the indemnification of
directors, officers, employees and other agents within the limitations permitted
by Section 317 and for the limitation on the personal liability of directors
permitted by Section 204(b)(10), subject to the exceptions required thereby.
II-1
ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
Exhibit
Numbers Description
------- -----------
4.1 Form of Warrant*
5.1 Opinion of Counsel**
23.1 Consent of Deloitte & Touche LLP**
* Incorporated by reference to BioTime's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on August 14, 2002.
** Filed herewith.
ITEM 17. UNDERTAKINGS.
Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers, and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the
Registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by final adjudication of
such issue.
II-2
The undersigned registrant hereby undertakes:
(1) To file during any period in which offers or sales are made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate
represent a fundamental change in the information set forth in the registration
statement;
(iii) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement.
(2) That for the purpose of determining any liability under the Securities
Act of 1933, each post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination of the
offering.
The undersigned registrant hereby undertakes that, for the purposes of
determining any liability under the Securities Act of 1922, each filing of the
registrant's annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
The undersigned undertakes that:
(1) For the purposes of determining any liability under the Securities Act
of 1933, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a form
of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or
497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.
(2) For the purposes of determining any liability under the Securities Act
of 1933, each post-effective amendment that contains a form of prospectus shall
be deemed to be a new
II-3
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the bona fide
offering thereof.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
has duly caused this Amendment to the Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Berkeley,
State of California on September 3, 2002.
BIOTIME, INC.
By /s/ Paul Segall
-------------------------------------
Paul Segall, Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this Amendment
to the Registration Statement has been signed below by the following persons in
the capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ Paul Segall Chief Executive Officer and September 3, 2002
---------------------------- Director (Principal Executive
PAUL SEGALL Officer)
/s/ Harold Waitz Vice President and Director September 3, 2002
----------------------------
HAROLD WAITZ
/s/ Hal Sternberg Vice President and Director September 3, 2002
----------------------------
HAL STERNBERG
/s/ Steven Seinberg Chief Financial Officer September 3, 2002
---------------------------- (Principal Financial and
STEVEN SEINBERG Accounting Officer)
/s/ Judith Segall Secretary and Director September 3, 2002
----------------------------
JUDITH SEGALL
---------------------------- Director ______ ___, 2002
JEFFREY B. NICKEL
II-4
----------------------------- Director ______ ___, 2002
MILTON H. DRESNER
----------------------------- Director ______ ___, 2002
KATHERINE GORDON
II-5
EXHIBIT INDEX
Exhibit
Numbers Description
------- -----------
4.1 Form of Warrant*
5.1 Opinion of Counsel**
23.1 Consent of Deloitte & Touche LLP**
* Incorporated by reference to BioTime's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission August 14, 2002.
** Filed herewith.